3 completed, 2 active not recruiting, 1 terminated, 1 unknown. 7 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Active not recruiting 2, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow EPA: new trials by email Literature Review of EPA trials Research Report on EPA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression Omega 3, Placebo - Treatment Resistant Depression, Inflammation | Phase 2 | Active not recruiting | Massachusetts General Hospital | 14 | 2025-01-30 | 2026-07-01 |
| Efficacy and Safety of Omega 3 Fatty Acid Supplements on Heavy Smokers Omega 3 fatty acid - Lung Cancer | Phase 2 | Unknown | British Columbia Cancer Agency | 42 | 2019-06-01 | 2019-05-07 |
| Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life EPA, Placebo - Prostate Cancer | Phase 2 | Active not recruiting | CHU de Quebec-Universite Laval | 130 | 2015-02-12 | 2026-10-23 |
| Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders Fish Oil, Safflower Oil - Epilepsy (Treatment Refractory) | Phase 2 / Phase 3 | Terminated | The Canadian College of Naturopathic Medicine | 6 | 2013-01-01 | 2023-02-10 |
| Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers Flaxseed oil, Paraffin + # 2 dye - Addictive Behavior, Abstinence Syndrome | Phase 2 / Phase 3 | Completed | Federal University of São Paulo | 30 | 2010-08-01 | 2011-07-12 |
| Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia Omega-3 Fatty Acids, Olive oil placebo, EPA fish oil concentrate; DHA fish oil concentrate - Schizophrenia, Fatty Acid Deficiency | Phase 2 / Phase 3 | Completed | University of Cincinnati | 2008-01-01 | 2011-08-02 | |
| Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation Eicosapentaenoic acid (omega-3 fatty acid), Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | University of Pittsburgh | 57 | 2005-09-01 | 2017-04-10 |
Depressive Disorder, Major (2) · Inflammation (2) · Schizophrenia (2) · Behavior, Addictive (1) · Bipolar Disorder (1) · Compulsive Behavior (1) · Coronary Artery Disease (1) · Depressive Disorder, Treatment-Resistant (1) · Epilepsy (1) · Hyperplasia (1) · Lung Neoplasms (1) · Overweight (1) · Prostatic Neoplasms (1) · Psychotic Disorders (1) · Seizures (1)
British Columbia Cancer Agency (1) · CHU de Quebec-Universite Laval (1) · Federal University of São Paulo (1) · Massachusetts General Hospital (1) · The Canadian College of Naturopathic Medicine (1) · University of Cincinnati (1) · University of Pittsburgh (1)
United States (3) · Canada (2) · Brazil (1)
Jeffrey K Yao, Ph.D., FACB (1) · Mac Burnham, PhD (1) · Mark H Rapaport, MD (1) · Neil Richtand, MD (1) · Paul A Hwang, MD (1) · Pedro L Prior, Student (1) · Peter Carlen, MD (1) · Stephen Lam, MD (1) · Vincent Fradet, MD, PhD (1)
PMID 29321047, PMID 34817851, PMID 36532545, PMID 37787025, PMID 38519581